Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list

Hepatology

Volumn 65, Issue 3, 2017, Pages 777-788

  Chhatwal, Jagpreet ^a   Samur, Sumeyye ^a   Kues, Brian ^b   Ayer, Turgay ^b   Roberts, Mark S ^c,d   Kanwal, Fasiha ^e,f   Hur, Chin ^a   Donnell, Drew Michael S ^c,d   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Georgia Institute of Technology   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; GRAFT SURVIVAL; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIFE EXPECTANCY; LIVER TRANSPLANTATION; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL PREDICTION; COHORT ANALYSIS; COMPARATIVE STUDY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; MALE; MARKOV CHAIN; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; PREOPERATIVE CARE; RISK ASSESSMENT; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; WAITING LISTS;

EID: 85008457806     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28926     Document Type: Article

References (40)

1. Rosen HR. Chronic hepatitis C infection. N Engl J Med 2011;364:2429-2438.
2. Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 2016;64:1442-1450.
3. Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Transl Hepatol 2014;2:124-133.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
5. Roche B, Samuel D. Hepatitis C virus treatment pre– and post–liver transplantation. Liver Int 2012;32:120-128.
6. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-2628.
7. Saxena V, Terrault N. Current management of hepatitis C virus: regimens for peri-liver transplant patients. Clin Liver Dis 2015;19:669-688.
8. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:2426-2433.
9. Carrion AF, Khaderi SA, Sussman NL. Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation. Liver Transpl 2016;22:279-280.
10. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis—pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 2016;23:408-418.
11. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force. Med Decis Making 2012;32:690-700.
12. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993;13:322.
13. Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-donor liver transplantation. Management Science 2004;50:1420-1430.
14. Van Arendonk KJ, Chow EKH, James NT, Orandi BJ, Ellison TA, Smith JM, et al. Choosing the order of deceased donor and living donor kidney transplantation in pediatric recipients: a Markov decision process model. Transplantation 2015;99:360-366.
15. Chow EK, Massie AB, Muzaale AD, Singer AL, Kucirka LM, Montgomery RA, et al. Identifying appropriate recipients for CDC infectious risk donor kidneys. Am J Transplant 2013;13:1227-1234.
16. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
17. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-697.
18. Gane E, Manns M, McCaughan G, Curry MP, Peck-Radosavljevic M, Vlierberghe HV, et al. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and -2 trials [Abstract]. Hepatology 2015;62(Suppl.):722A-723A. Abstract 1049.
19. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015;21:823-830.
20. Shechter SM, Bryce CL, Alagoz O, Kreke JE, Stahl JE, Schaefer AJ, et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 2005;25:199-209.
21. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008;14(Suppl. 2):S58-S66.
22. Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009;22:172-181.
23. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
24. Lai JC, O'Leary JG, Trotter JF, Verna EC, Brown RS Jr, Stravitz RT, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody–positive donors: a multicenter cohort study. Liver Transpl 2012;18:532-538.
25. Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-638.
26. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth B, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425.
27. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400.
28. Tapper EB, Hughes M, Buti M, Dufour J-F, Flamm S, Curry M, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C cirrhosis: a cost-effectiveness analysis. Transplantation 2016; in press.
29. Njei B, McCarty TR, Ditah IC, Lim JK, Fortune BE. 504 Optimal timing for hepatitis C treatment in cirrhotic patients awaiting liver transplantation: a cost-effectiveness analysis. Gastroenterology 2015;150:S1037.
30. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010;16:748-759.
31. Cheung M, Foster G, Irving W, McLauchlan J, Walker A, Hudson B, et al. Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study. Lancet 2016;387:S26.
32. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C in the United States: model-based predictions. Ann Intern Med 2014;161:170-180.
33. US Department of Health and Human Services. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/. Accessed March 2016.
34. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010;10:1003-1019.
35. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
36. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
37. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000;7:87-92.
38. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397-406.
39. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis. Br J Cancer 2008;98:1166-1175.
40. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 Infection in the United States. Value Health 2013;16:973-986.